Clinical trials: Treatment Resistant Major Depression
Major Depressive Disorder, Insulin Resistance
Pioglitazone in Patients With Mood Disorders
The purpose of this study is to see how an insulin sensitizing medication, Pioglitazone, can cause changes in mood in some depressed patients. Study participants receive assessment of their cognitive and metabolic functioning.
- Trial name
- NCT01559857
- Testing
- Pioglitazone, Sugar Pill
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Stanford University
Treatment Resistant Depression
TBS in Major Depression
Background Major depression is associated with morbidity and increased mortality. Along with the psychological strain depression represents a high socioeconomic burden costing Europe more than €113 billion/year.
- Trial name
- NCT03257397
- Testing
- theta-burst stimulation (TBS) using a MagPro X1000
- Where
- Austria
- Volunteers
- 80 people
- Sponsor
- Rupert Lanzenberger
Major Depressive Disorder
Pharmacogenomics for Antidepressant Guidance and Education 1 (PAGE-1_AG1)
One-third or more of individuals treated for major depressive disorder (MDD) do not experience remission of symptoms despite at least two adequate antidepressant trials.
- Trial name
- PAGE-1_AG1 (NCT01426516)
- Testing
- Genecept Assay
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Genomind, LLC
Major Depressive Disorder, Treatment Resistant Depression
Deep Brain Stimulation (DBS) Therapy for Treatment Resistant Depression
We propose a clinical study of medial forebrain bundle DBS as a treatment in 20 patients with treatment refractory depression (TRD).
- Trial name
- NCT02046330
- Testing
- Deep Brain Stimulation Model 3387 Model 3389
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- The University of Texas Health Science Center, Houston
Depression, Unipolar
Pulsed Electro Magnetic Fields (PEMF) in Depression
PEMF (Pulsed Electro Magnetic Fields) therapy has been used to stimulate bone repair in non-union since the 1970s. This is an accepted use, which has been approved by the Food and Drug Administration in the US.
- Trial name
- PEMF (NCT03556735)
- Testing
- Treatment with PEMF equipment
- Where
- Denmark
- Volunteers
- 59 people
- Sponsor
- University of Southern Denmark
Treatment-Resistant Depression, Major Depressive Disorder
Observation of Safety and Tolerability Within 1 Year of the Use of R-ketamine / Placebo in Drug-resistant Depression
An observational-comparative study, without interfering with the treatment, based on an operationalized interview.
- Trial name
- NCT06232291
- Where
- Poland
- Volunteers
- 3 people
- Sponsor
- Medical University of Gdansk
Major Depressive Disorder, Treatment Resistant Depression
40 Hz Light Neurostimulation for Patients With Depression (FELIX)
Recent research in mice models of Alzheimer's disease (AD) has demonstrated that one hour per day of exposure to 40 Hz flickering light therapy can halt the disease's progression, and improve cognition and memory.
- Trial name
- NCT05680220
- Testing
- Neurostimulation System (NSS): Active Setting
- Where
- Denmark
- Volunteers
- 60 people
- Sponsor
- Klaus Martiny
Major Depressive Disorder
The Antidepressant Advisor (Study 3): fMRI Study to Predict Treatment Response in Patients With Depression
This prospective observational study (ADeSS-Study3) investigates candidate biomarkers prospectively predicting response to antidepressant medications and prognosis in major depressive disorder (MDD).
- Trial name
- ADeSS_S3 (NCT04342299)
- Where
- United Kingdom
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- King's College London
Suicide, Depressive Disorder, Treatment-Resistant
Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression
Background: Major depressive disorder (MDD) is a serious mental illness that can put people at risk of self-harm and death. Many drugs are used to treat MDD, but it can take a long time for them to be effective.
- Conditions
- Suicide, Depressive Disorder, Treatment-Resistant, Ketamine, Molecular Mechanisms of Pharmacological Action
- Trial name
- NCT06511908
- Testing
- (2R,6R)-hydroxynorketamine (0.25 to 2.0 mg/kg)
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Institute of Mental Health (NIMH)
Major Depressive Disorder, Treatment Resistant Depression
Ketamine Associated ACC GABA and Glutamate Change and Depression Remission:
This is a feasibility study and the goal of this project is to evaluate whether peak ACC GABA and glutamate, quantified as a CSF-corrected absolute concentration percent change from baseline, is associated with clinical…
- Conditions
- Major Depressive Disorder, Treatment Resistant Depression, Bipolar Depression
- Trial name
- NCT03573349
- Testing
- Ketamine
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Mayo Clinic
Major Depressive Disorder, Deep Brain Stimulation
The Efficacy and Prediction of Deep Brain Stimulation for Treatment-resistant Depression
Several open-label trials have shown the therapeutic promise of deep brain stimulation (DBS) targeted to striatal and surrounding capsular areas in treatment-resistant depression (TRD).
- Trial name
- NCT04530942
- Testing
- Deep brain stimulation(Active)
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Ruijin Hospital
Major Depressive Disorder, Treatment Resistant Depression
Identifying Local Field Potential Biomarkers for Treatment-Resistant Major Depression With Deep Brain Stimulation
Major depressive disorder (MDD) is a complex and severe mental illness, characterized by multiple symptoms, and is a leading cause of non-fatal health loss.
- Trial name
- NCT06542094
- Testing
- Deep Brain stimulation
- Where
- China
- Volunteers
- 12 people
- Sponsor
- West China Hospital
Major Depressive Disorder, Treatment Resistant Depression
Comparing Quetiapine XR Monotherapy and Augmentation With Lithium Augmentation in TRD Patients
The primary objective of the study is to evaluate the efficacy of Quetiapine extended release (XR) in combination with an selective serotonin reuptake inhibitor (SSRI) or Venlafaxine versus Lithium in combination with an…
- Trial name
- RUBY (NCT00789854)
- Testing
- Quetiapine XR, Lithium carbonate, SSRI/Venlafaxine
- Where
- 106 sites in Australia, Austria and 11 more
- Volunteers
- 688 people
- Sponsor
- AstraZeneca
Major Depression Moderate, Major Depression Severe
EEG Microstate and Neuroinflammatory Biomarkers in Older Age Patients With Major Depressive Disorder Receiving ECT
This study aims to investigate the neurophysiological and inflammatory changes associated with electroconvulsive therapy (ECT) in older age patients diagnosed with Major Depressive Episode, Major Depression, and Bipolar Disorder…
- Conditions
- Major Depression Moderate, Major Depression Severe, Major Depression With Comorbid Anxiety Symptoms, Major Depression With Panic Attacks
- Trial name
- NCT07740694
- Testing
- Electroconvulsive Therapy
- Where
- Turkey (Türkiye)
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Istanbul University - Cerrahpasa
Major Depressive Disorder
Pivotal Trial (D02) of Vagus Nerve Stimulation (VNS) for Treatment-Resistant Depression (TRD)
To confirm the safety and efficacy of the NCP System in treating patients in a nmajor depressive episode.
- Trial name
- NCT00533832
- Testing
- vagus nerve stimulation (VNS)
- Where
- United States
- Volunteers
- 266 people
- Sponsor
- Cyberonics, Inc.
Treatment Resistant Depression, Major Depressive Disorder
Biomarker-guided rTMS for Treatment Resistant Depression
Repetitive transcranial magnetic stimulation (rTMS) is a treatment for depression. The investigators are continuing to learn how to optimize outcomes from rTMS treatment.
- Trial name
- BioTMS (NCT04041479)
- Testing
- Repetitive Transcranial Magnetic Stimulation
- Where
- 2 sites in United States
- Volunteers
- 348 people
- Sponsor
- Weill Medical College of Cornell University
Major Depression
Conventional Bilateral rTMS vs. Bilateral Theta Burst Stimulation for Late-Life Depression
This trial will compare conventional sequential bilateral rTMS to a bilateral theta burst stimulation protocol. The right and left dorsolateral prefrontal cortices will be the site of stimulation in both treatment conditions.
- Trial name
- NCT02998580
- Testing
- LFR followed by HFL, cTBS followed by iTBS
- Where
- Canada
- Volunteers
- 163 people
- Sponsor
- Centre for Addiction and Mental Health
Depression, Suicide
Ketamine for Depression and Suicide Risk
The purpose of this research study was to find out if the medication known as ketamine could help the symptoms of depression. This drug is approved by the U.S.
- Trial name
- Ketamine (NCT02094898)
- Testing
- Ketamine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Mayo Clinic
Treatment-resistant Depression (TRD), Major Depression
Relationship of Peripheral Inflammatory and Neuroprotective Biomarkers With Response to Intermittent Theta Burst Stimulation in Treatment-Resistant Depression
Treatment-resistant depression (TRD) is a major clinical challenge affecting a substantial proportion of patients with major depressive disorder who do not adequately respond to conventional antidepressant treatments.
- Trial name
- TRD-BIOTMS (NCT07673913)
- Testing
- Intermittent Theta Burst Stimulation (iTBS)
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Gulhane Training and Research Hospital
Depressive Disorder, Treatment-Resistant
DBS for Treatment Resistant Depression
The purpose of this study is to examine the effects of sub-callosal cingulate (SCC) deep brain stimulation (DBS) in patients with treatment resistant depression (TRD).
- Trial name
- CRIO-DBS (NCT01983904)
- Testing
- deep brain stimulation with short & long pulse width
- Where
- Canada
- Volunteers
- 22 people
- Sponsor
- University of Calgary